Evidence map›Paper›PMID 30538443›Full record

SynthesisInternational journal of chronic obstructive pulmonary disease

Long-term macrolide treatment for the prevention of acute exacerbations in COPD: a systematic review and meta-analysis.

Yanan Cui, Lijuan Luo, Chenbei Li, Ping Chen, Yan Chen

Open access · goldAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in International journal of chronic obstructive pulmonary disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 2 pooled it
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 55 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Isolation ofJournal of clinical medicine · 2023
    Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. The Role of Non-TypeableFrontiers in cellular and infection microbiology · 2021
    Review
  20. Clinical Characteristics and Outcomes of Patients with Severe COVID-19 and Chronic Obstructive Pulmonary Disease (COPD).Medical science monitor : international medical journal of experimental and clinical research · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Yanan CuiDepartment of Respiratory Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China, chenyan99727@csu.edu.cn.
Lijuan LuoDepartment of Respiratory Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China, chenyan99727@csu.edu.cn.
Chenbei LiBiomedical Clinical Medicine, The Queen Marry University of London of Nanchang University, Jiangxi, China.
Ping ChenDepartment of Respiratory Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China, chenyan99727@csu.edu.cn.
Yan ChenDepartment of Respiratory Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China, chenyan99727@csu.edu.cn.
Central South University · CNNanchang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAcute exacerbation of COPD (AECOPD) is associated with an increased hospitalization and mortality. Azithromycin and erythromycin are the recommended drugs to reduce the risk of exacerbations. However, the most suitable duration of therapy and drug-related adverse events are still a matter of debate. The aim of this meta-analysis was to assess the current evidence regarding the efficacy and safety of long-term macrolide treatment for COPD. MATERIALS AND

methodsWe comprehensively searched PubMed, Embase, the Cochrane Library, and the Web of Science and performed a systematic review and cumulative meta-analysis of all randomized controlled trials (RCTs) and retrospective studies.

resultsEleven RCTs and one retrospective study including a total of 2,151 cases were carried out. Long-term macrolide treatment significantly reduced the total number of cases with one or more exacerbations (OR=0.40; 95% CI=0.24-0.65;

conclusionProphylactic azithromycin or erythromycin treatment has a significant effect in reducing the frequency of AECOPD in a time-dependent manner. However, long-term macrolide treatment could increase the occurrence of adverse events and macrolide resistance. Future large-scale, well-designed RCTs with extensive follow-up are required to identify patients in whom the benefits outweigh risks.

Indexed as

AgedAnti-Bacterial AgentsAzithromycinDisease ProgressionDrug Administration ScheduleDrug Resistance, BacterialErythromycinFemaleHumansLungMalePulmonary Disease, Chronic ObstructiveRespiratory Tract InfectionsRisk FactorsTime FactorsTreatment OutcomeAnti-Bacterial AgentsAzithromycinErythromycinadverse eventsAECOPDazithromycinmacrolide

Identifiers

PMID30538443
PMCPMC6254503
OpenAlexW2901487983

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.